CLINICAL TRIALS PROFILE FOR PEANUT
✉ Email this page to a colleague
All Clinical Trials for peanut
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00086606 ↗ | A Safety and Efficacy Study of Xolair in Peanut Allergy | Terminated | Genentech, Inc. | Phase 2 | 2004-06-01 | This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein. |
| NCT00379158 ↗ | Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana | Completed | Nestlé Foundation | Phase 4 | 2003-10-01 | 1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only. 3. Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles. |
| NCT00379158 ↗ | Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana | Completed | United States Agency for International Development (USAID) | Phase 4 | 2003-10-01 | 1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only. 3. Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles. |
| NCT00379158 ↗ | Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana | Completed | University of California, Davis | Phase 4 | 2003-10-01 | 1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only. 3. Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles. |
| NCT00382148 ↗ | A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g | Completed | Genentech, Inc. | Phase 2 | 2006-11-01 | This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for peanut
Condition Name
Clinical Trial Locations for peanut
Trials by Country
Clinical Trial Progress for peanut
Clinical Trial Phase
Clinical Trial Sponsors for peanut
Sponsor Name
